Compare Godaddy Inc (GDDY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs Recursion Pharmaceuticals Inc — how do they compare? Godaddy Inc trades at $90.47 (market cap $11.49B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: Godaddy Inc is far larger — about 6.3× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| GDDY | RXRX | |
|---|---|---|
Market Cap | $11.49B | $1.81B |
Sector | Technology | Health |
52-Week High | $148.88 | $6.79 |
52-Week Low | $75.07 | $2.84 |
Enterprise Value | $14.18B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $91.49, up 0.46% today, with a neutral technical signal and strong fundamentals including a 17.83% net income margin and consistent earnings beats. Revenue growth is steady, projected at $5.1B for 2026, while recent news highlights legal investigations into potential securities violations, creating investor uncertainty.
The stock offers value with a P/E of 13.48 and a consensus price target of $112.13, but risks include ongoing legal scrutiny and high debt levels. Analyst sentiment remains bullish with 57% buy ratings, though technical indicators suggest near-term consolidation around key support at $90.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
